AstraZeneca buys Actavis' North American respiratory business
This article was originally published in Scrip
Executive Summary
AstraZeneca is to acquire the rights to Actavis' branded respiratory business in the US and Canada, paying $600m plus low single-digit royalties above a certain revenue threshold.